107 related articles for article (PubMed ID: 10570415)
1. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis.
Yoshikawa T; Saitoh M; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer; 1999 Nov; 86(10):1929-35. PubMed ID: 10570415
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer Lett; 2000 Apr; 151(1):81-6. PubMed ID: 10766426
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomartker for invasion and its impact on survival.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer; 2001 May; 91(9):1739-44. PubMed ID: 11335899
[TBL] [Abstract][Full Text] [Related]
5. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
[TBL] [Abstract][Full Text] [Related]
7. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Miyagi Y
Gastric Cancer; 2006; 9(2):106-13. PubMed ID: 16767366
[TBL] [Abstract][Full Text] [Related]
8. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in peripheral blood of patients with gastric carcinoma].
Yoshikawa T; Suzuki K; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y; Tsuburaya A
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1461-4. PubMed ID: 9703854
[TBL] [Abstract][Full Text] [Related]
10. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
11. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer.
Kemik O; Kemik AS; Sümer A; Dulger AC; Adas M; Begenik H; Hasirci I; Yilmaz O; Purisa S; Kisli E; Tuzun S; Kotan C
World J Gastroenterol; 2011 Apr; 17(16):2109-12. PubMed ID: 21547130
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma.
Gaspar MJ; Arribas I; Coca MC; Díez-Alonso M
Tumour Biol; 2001; 22(5):318-22. PubMed ID: 11553862
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma.
Seo YS; Park JJ; Kim JH; Kim JY; Yeon JE; Kim JS; Byun KS; Bak YT
Dig Dis Sci; 2007 Mar; 52(3):753-9. PubMed ID: 17237995
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
Kim JH; Jun KH; Jung H; Park IS; Chin HM
Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for peritoneal dissemination of gastric cancer.
Yeldan E; Oguz S; Usta U; Ilhan E; Senlikci A
Minerva Chir; 2015 Apr; 70(2):91-6. PubMed ID: 25815699
[TBL] [Abstract][Full Text] [Related]
17. Levels of carcinoembryonic antigen and CA 19-9 in the sera and peritoneal washing of patients undergoing surgical treatment for gastric carcinoma.
Crepaldi-Filho R; Palma RT; Giusti MF; Bueno Mde A; Silva PS; Waisberg J
Arq Gastroenterol; 2008; 45(3):219-24. PubMed ID: 18852950
[TBL] [Abstract][Full Text] [Related]
18. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
[TBL] [Abstract][Full Text] [Related]
19. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.
Murakami S; Satomi A; Ishida K; Murai H; Matsuki M; Hashimoto T
Cancer; 1994 Nov; 74(10):2745-8. PubMed ID: 7525035
[TBL] [Abstract][Full Text] [Related]
20. Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer.
Yoshikawa T; Cho H; Tsuburaya A; Kobayashi O
Gastric Cancer; 2009; 12(1):31-6. PubMed ID: 19390929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
